STRADEFY BIOSCIENCES
Pioneering next-generation Bioadhesive Drug Carriers (BDCs)
BDC'S
STRATEGY
STRATEGY
BDC's maximize the efficacy of active drug product by optimizing retention and internalization in target tissues and cells. They are analogous to ADCs with higher active drug loads and differentiated retention and cell internalization.
STRATEGY
STRATEGY
STRATEGY
Our lead candidate has demonstrated efficacy in multiple oncology models. We have a capital efficient path to obtain proof of concept in targeted oncology.
RESEARCH
STRATEGY
RESEARCH
Stradefy is based on the research of Mark Saltzman and Mike Girardi at Yale University, and has strong patent protection.
LEADERSHIP
Mark Saltzman, Ph.D
Jeffrey Goldberg, MS, MBA
Michael Girardi, M.D.
Academic Founder
Goizueta Foundation
Professor of Chemical and Biomedical Engineering
Yale University
Michael Girardi, M.D.
Jeffrey Goldberg, MS, MBA
Michael Girardi, M.D.
Academic Founder
Vice Chair & Evans Prof of Dermatology
Yale School of Medicine
Jeffrey Goldberg, MS, MBA
Jeffrey Goldberg, MS, MBA
Jeffrey Goldberg, MS, MBA
Executive Chair
Jeff Goldberg is Executive Chair of Stradefy Biosciences and an advisor to several other therapeutics companies. Previously, he served as CEO of Aeglea
BioTherapeutics, CEO of Immunitas Therapeutics, and COO of Akcea Therapeutics.
Brian Dixon, Ph.D.
Jeffrey Goldberg, MS, MBA
Jeffrey Goldberg, MS, MBA
Venture Partner
Brian is a Venture Partner at Elm Street Ventures. Prior to ESV he was CEO of BioRelix, Inc., and prior to that he directed drug discovery, DPMK, and other key R&D activities at Bayer.